Close Menu

NEW YORK – Celcuity on Tuesday said it will use its CELSignia Multi-Pathway Activity Test to identify breast cancer patients eligible for enrollment in a Phase II clinical trial evaluating the combination of Novartis' c-Met inhibitor capmatinib (Tabrecta) and Puma Biotechnology's pan-HER inhibitor neratinib (Nerlynx).

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.